Sullivan Lynne Marie 4
4 · Unity Biotechnology, Inc. · Filed May 12, 2023
Insider Transaction Report
Form 4
Sullivan Lynne Marie
CFO & Head of Corp. Dev.
Transactions
- Award
Stock Option (Right to Buy)
2023-05-11$2.77/sh+40,000$110,800→ 40,000 totalExercise: $2.77Exp: 2033-05-11→ Common Stock (40,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-11−24,000→ 0 totalExercise: $99.60Exp: 2030-08-01→ Common Stock (24,000 underlying) - Award
Stock Option (Right to Buy)
2023-05-11+24,000→ 24,000 totalExercise: $2.77Exp: 2030-08-01→ Common Stock (24,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-11−12,333→ 0 totalExercise: $41.80Exp: 2031-06-24→ Common Stock (12,333 underlying) - Award
Stock Option (Right to Buy)
2023-05-11+12,333→ 12,333 totalExercise: $2.77Exp: 2031-06-24→ Common Stock (12,333 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2023-05-11−20,000→ 0 totalExercise: $10.60Exp: 2032-02-09→ Common Stock (20,000 underlying) - Award
Stock Option (Right to Buy)
2023-05-11+20,000→ 20,000 totalExercise: $2.77Exp: 2032-02-09→ Common Stock (20,000 underlying)
Footnotes (7)
- [F1]The underlying shares vest and become exercisable pursuant to the following schedule: One-eighth of the shares subject to the option vest in successive, equal quarterly installments starting on August 11, 2023, subject to the Reporting Person's continued service to Issuer through the applicable vesting date.
- [F2]The underlying shares vest and become exercisable pursuant to the following schedule: Twenty Five Percent (25%) of the shares subject to the option vested on August 1, 2021 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
- [F3]On May 11, 2023, the option originally granted to the Reporting Person on August 1, 2020 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
- [F4]Shares subject to the stock option vest and become exercisable in successive, equal monthly installments over a 48-month period commencing on June 24, 2021 (the "Vesting Commencement Date"), so that 100% of the shares become fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- [F5]On May 11, 2023, the option originally granted to the Reporting Person on June 24, 2021 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.
- [F6]The underlying shares vest and become exercisable pursuant to the following schedule: One Third of the shares subject to the option vest on February 9, 2023 (the "Vesting Commencement Date"), and the remaining shares subject to the option vest in 24 successive, equal monthly installments thereafter on each monthly anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through the applicable vesting date.
- [F7]On May 11, 2023, the option originally granted to the Reporting Person on February 9, 2022 was amended to reduce the exercise price to $2.77 per share. All of the other terms of the option remain unchanged.